Company Registration No. 05386828 (England and Wales)
MDNA LIFE SCIENCES (UK) LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
30 SEPTEMBER 2025
PAGES FOR FILING WITH REGISTRAR
A6 Kingfisher House
Kingsway
Team Valley Trading Estate
Gateshead
NE11 0JQ
MDNA LIFE SCIENCES (UK) LTD
CONTENTS
Page
Company information
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
MDNA LIFE SCIENCES (UK) LTD
BALANCE SHEET
AS AT
30 SEPTEMBER 2025
30 September 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
22,262
64,978
Current assets
Debtors
4
18,284
5,747
Cash at bank and in hand
32,485
16,264
50,769
22,011
Creditors: amounts falling due within one year
5
(205,793)
(418,436)
Net current liabilities
(155,024)
(396,425)
Total assets less current liabilities
(132,762)
(331,447)
Creditors: amounts falling due after more than one year
6
(3,750,055)
(3,363,037)
Net liabilities
(3,882,817)
(3,694,484)
Capital and reserves
Called up share capital
1
1
Profit and loss reserves
(3,882,818)
(3,694,485)
Total equity
(3,882,817)
(3,694,484)

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 September 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

MDNA LIFE SCIENCES (UK) LTD
BALANCE SHEET (CONTINUED)
AS AT
30 SEPTEMBER 2025
30 September 2025
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 28 March 2026 and are signed on its behalf by:
Mr H E Smart
Director
Company registration number 05386828 (England and Wales)
MDNA LIFE SCIENCES (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 3 -
1
Accounting policies
Company information

MDNA Life Sciences (UK) Ltd is a private company limited by shares incorporated in England and Wales. The registered office is A6 Kingfisher House, Kingsway, Team Valley Trading Estate, Gateshead, NE11 0JQ.

1.1
Accounting convention

The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

1.2
Going concern

A true t the time of approving the financial statements, t he directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus t he directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold buildings
over 50 years
Plant and machinery
over 5 years
Fixtures and fittings
over 5 years
Leasehold land and buildings
over the lease term

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Taxation
MDNA LIFE SCIENCES (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 4 -

A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

1.6
Provisions

Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.

1.7
Pension

Contributions to defined contribution plans are expensed in the period to which they relate.

1.8
Leases

A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership. All other leases are classified as operating leases. The rights of use and obligations under finance leases are initially recognised as assets and liabilities at amounts equal to the fair value of the leased assets or, if lower, the present value of the minimum lease payments. Minimum lease payments are apportioned between the finance charge and the reduction in the outstanding liability using the effective interest rate method. The finance charge is allocated to each period during the lease so as to produce a constant periodic rate of interest on the remaining balance of the liability. Leased assets are depreciated in accordance with the company's policy for tangible fixed assets. If there is no reasonable certainty that ownership will be obtained at the end of the lease term, the asset is depreciated over the lower of the lease term and its useful life. Operating lease payments are recognised as an expense on a straight line basis over the lease term.

1.9
Foreign currency translation

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

MDNA LIFE SCIENCES (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.10

Debtors

Short term debtors are measured at transaction price which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method,less any impairment losses for bad and doubtful debts. Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
3
8
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 October 2024 and 30 September 2025
424,801
Depreciation and impairment
At 1 October 2024
359,823
Depreciation charged in the year
42,716
At 30 September 2025
402,539
Carrying amount
At 30 September 2025
22,262
At 30 September 2024
64,978
MDNA LIFE SCIENCES (UK) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2025
- 6 -
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
-
0
1,830
Other debtors
18,284
3,917
18,284
5,747
5
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
10,872
10,872
Trade creditors
18,203
38,188
Taxation and social security
593
1,388
Other creditors
176,125
367,988
205,793
418,436
6
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
75,643
84,484
Amounts owed to group undertakings
3,674,412
3,278,553
3,750,055
3,363,037
7
Parent company

The company is wholly owned subsiduary of MDNA Life Sciences Inc, a company incorporated in the USA.

2025-09-30 2024-10-01 false false false 28 March 2026 CCH Software CCH Accounts Production 2025.300 No description of principal activity Mr C A Hill Mr H E Smart Mr H E Smart 05386828 2024-10-01 2025-09-30 05386828 2025-09-30 05386828 2024-09-30 05386828 core:OtherPropertyPlantEquipment 2025-09-30 05386828 core:OtherPropertyPlantEquipment 2024-09-30 05386828 core:CurrentFinancialInstruments core:WithinOneYear 2025-09-30 05386828 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-30 05386828 core:Non-currentFinancialInstruments core:AfterOneYear 2025-09-30 05386828 core:Non-currentFinancialInstruments core:AfterOneYear 2024-09-30 05386828 core:CurrentFinancialInstruments 2025-09-30 05386828 core:CurrentFinancialInstruments 2024-09-30 05386828 core:Non-currentFinancialInstruments 2025-09-30 05386828 core:Non-currentFinancialInstruments 2024-09-30 05386828 core:ShareCapital 2025-09-30 05386828 core:ShareCapital 2024-09-30 05386828 core:RetainedEarningsAccumulatedLosses 2025-09-30 05386828 core:RetainedEarningsAccumulatedLosses 2024-09-30 05386828 bus:CompanySecretaryDirector1 2024-10-01 2025-09-30 05386828 core:FurnitureFittings 2024-10-01 2025-09-30 05386828 2023-10-01 2024-09-30 05386828 core:OtherPropertyPlantEquipment 2024-09-30 05386828 core:OtherPropertyPlantEquipment 2024-10-01 2025-09-30 05386828 bus:PrivateLimitedCompanyLtd 2024-10-01 2025-09-30 05386828 bus:SmallCompaniesRegimeForAccounts 2024-10-01 2025-09-30 05386828 bus:FRS102 2024-10-01 2025-09-30 05386828 bus:AuditExemptWithAccountantsReport 2024-10-01 2025-09-30 05386828 bus:Director1 2024-10-01 2025-09-30 05386828 bus:Director2 2024-10-01 2025-09-30 05386828 bus:CompanySecretary1 2024-10-01 2025-09-30 05386828 bus:FullAccounts 2024-10-01 2025-09-30 xbrli:pure xbrli:shares iso4217:GBP